Jake Shortt

Personal profile

Biography

Associate Professor Jake Shortt is the Head of Haematology Research at the School of Clinical Sciences and clinical lead at Monash Haematology for leukaemia and myelodysplasia. He is Principal Investigator on a range of clinical trials for myeloid malignancies, conducted through the Monash Haematology clinical trials unit. He is also a Principal Investigator on academically-funded and investigator-initiated trials in multiple myeloma and lymphoma.

Associate Professor Shortt is the recipient of a Medical Research Future Fund Career Development Fellowship as part of the Next Generation Clinical Researchers Program. His strong translational work in the School of Clinical Sciences is focused on strategies incorporating epigenetic drugs with immunotherapy in haematological cancers, particularly lymphoma and multiple myeloma. He heads the Blood Cancer Therapeutics laboratory within the Monash Health Translation Precinct, facilitating bench-to-bedside research in order to progress these new treatments into the haematology clinic.

In addition to his clinical and research roles, Associate Professor Shortt is the Chair of the Laboratory Sciences Committee of the Australasian Leukaemia and Lymphoma Group and sits on the steering committees of the Australian TTP registry, the Australian Lymphoma and Related Diseases Registry and the Victorian Epigenetics Group.

Clinical activities

Associate Professor Shortt is clinical lead at Monash Health for leukaemia and myelodysplasia. He is also the Deputy Unit Head of Laboratory Haematology. He attends the Monash Haematology myeloid disorders clinic and runs a sub-specialty service for patients with chronic myeloid leukaemia. In addition to outpatient clinics, Associate Professor Shortt undertakes inpatient ward service at Monash Health, and is Principal Investigator at Monash Health for a range of clinical trials in leukaemia and myelodysplasia.

External positions

Honorary Principal Fellow, University of Melbourne

31 Jan 2019 → …

Honorary Senior Research Scientist, Peter MacCallum Cancer Centre

1 Oct 2015 → …

Consultant Haematologist, Monash Health

1 Feb 2008 → …

Research area keywords

Cancer Immunology
Epigenetics
Leukemia
Lymphoma
Molecular Oncology
Myelodysplasia
Myeloma
Thrombotic thrombocytopenic purpura
cMYC

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2024

5 Finished
18 Active

A qualitative study exploring patient and healthcare provider experiences of transfusion in myelodysplastic syndromes (MDS): Phase 2 of the REDDS2 trial

McQuilten, Z., Mo, A., Pritchard, E., Shortt, J., Wood, E. & Stanworth, S.

National Blood Authority

5/12/19 → 30/10/22

Project: Research

A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (RE-DIRECT)

Shortt, J.

28/11/19 → 27/11/24

Project: Research

A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Shortt, J.

30/08/19 → 29/08/24

Project: Research

A Phase I study of MAX-40279 given orally to patients with acute myelogenous leukemia (AML)

Shortt, J.

13/08/19 → 12/08/24

Project: Research

A Phase 2, international, multicenter, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (Oral Azacitidine) Alone and in combination with the Durvalumab (MEDI14736) in subjects with Myelodysplastic Syndromes who fail to achieve an Objective response to treatment with Azacitidine for Injection of Decitabine

Shortt, J.

12/06/19 → 11/06/24

Project: Research

Research Output 1998 2019

51 Article
18 Letter
5 Review Article
2 Chapter (Book)
3 More
- 2 Meeting Abstract
- 1 Editorial

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

Phillips, D. C., Jin, S., Gregory, G. P., Zhang, Q., Xue, J., Zhao, X., Chen, J., Tong, Y., Zhang, H., Smith, M., Tahir, S. K., Clark, R. F., Penning, T. D., Devlin, J. R., Shortt, J., Hsi, E. D., Albert, D. H., Konopleva, M., Johnstone, R. W., Leverson, J. D. & 1 others, Souers, A. J., 11 Dec 2019, (Accepted/In press) In : Leukemia. 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma

Ratnasingam, S., Casan, J., Shortt, J., Hawkes, E., Gilbertson, M., McQuilten, Z., Grigoriadis, G., Htun, K. T., Htet, S. M., Campbell, P., Chai, K. L., Quach, H., Patil, S. & Opat, S., 19 Sep 2019, In : Scientific Reports. 9, 1, 7 p., 13544.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care

Casan, J. ML., Barraclough, A., Shortt, J. & Hawkes, E. A., 1 Mar 2019, In : The Lancet Haematology. 6, 3, p. e119 1 p.

Research output: Contribution to journal › Letter › Other › peer-review

Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival

Arthur, C., Jeffrey, A., Yip, E., Katsioulas, V., Nalpantidis, A., Kerridge, I., Greenwood, M., Coyle, L., Mackinlay, N., Fay, K., Enjeti, A., Shortt, J. & Stevenson, W., 6 Dec 2019, (Accepted/In press) In : Leukemia and Lymphoma. 9 p.

Research output: Contribution to journal › Article › Research › peer-review